The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Interventions for structural heart disease
CoreValve Evolut R implantation as valve-in-valve in an Edwards SAPIEN 3 to treat paravalvular regurgitation
EuroIntervention 2015;11:e1 published online e-article September 2015. DOI: 10.4244/EIJV11I5A116
Giuseppe Bruschi1*, MD; Francesco Soriano1, MD; Francesco Musca1, MD; Stefano Nava1, MD; Arturo Einaudi2, MD; Andrea Garascia1, MD; Oriana Belli1, MD; Alberto Barosi1, MD; Pasquale Fratto1, MD; Paola Colombo1, MD, PhD; Claudio Francesco Russo1, MD; Maria Pia Gagliardone2, MD; Silvio Klugmann1, MD
1. Cardiology & Cardiac Surgery Department, Niguarda Ca’ Granda Hospital, Milan, Italy; 2. Cardiothoracic Anesthesia and Intensive Care, Niguarda Ca’ Granda Hospital, Milan, Italy
A 75-year-old male underwent transfemoral transcatheter aortic valve implantation (TAVI) with a 23 mm SAPIEN 3 (Edwards Lifesciences Inc., Irvine, CA, USA). One year after, he was admitted to our department for pulmonary oedema. Echocardiographic evaluation evidenced low placement of the SAPIEN 3 and 3-(4)+/4+ aortic regurgitation. ECG-gated multislice computed tomography (MSCT) was performed which confirmed low placement (Moving image 1) and underexpansion of the SAPIEN 3 with a perimeter of 62 mm and diameter of 20 mm (Figure 1A-Figure 1C). After Heart Team evaluation, a new TAVI procedure was preferred with the implantation of a 26 mm CoreValve® Evolut R™ (Medtronic, Minneapolis, MN, USA). Basal aortography evidenced ...